Literature DB >> 18536698

Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.

Stella G Giakoumaki1, Panos Roussos, Panos Bitsios.   

Abstract

Recent evidence suggests that prepulse inhibition (PPI) levels relate to executive function possibly by a prefrontal cortex (PFC) dopamine (DA) link. We explored the effects of enhanced PFC DA signaling by the nonstimulant catechol-O-methyltransferase (COMT) inhibitor tolcapone, on PPI and working memory of subjects homozygous for the Val (low PFC DA) and the Met (high PFC DA) alleles of the COMT Val158Met polymorphism. Twelve Val/Val and eleven Met/Met healthy male subjects entered the study. Tolcapone 200 mg was administered in two weekly sessions, according to a balanced, crossover, double-blind, placebo-controlled design. PPI was assessed with 5 dB and 15 dB above background prepulses, at 30-, 60-, and 120 ms prepulse-pulse intervals. Subjects also underwent the n-back and the letter-number sequencing (LNS) tasks. PPI was lower in the Val/Val compared to the Met/Met group in the placebo condition. Tolcapone increased PPI significantly in the Val/Val group and tended to have the opposite effect in the Met/Met group. Baseline startle was not affected by tolcapone in the Val/Val group but it was slightly increased in the Met/Met group. Tolcapone improved performance in the n-back and LNS tasks only in the Val/Val group. Enhancement of PFC DA signaling with tolcapone improves both PPI and working memory in a COMT Val158Met genotype-specific manner. These results suggest that early information processing and working memory may both depend on PFC DA signaling, and that they may both relate to PFC DA levels according to an inverted U-shaped curve function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536698     DOI: 10.1038/npp.2008.82

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  61 in total

1.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.

Authors:  K A Perkins; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

3.  The genetic basis of addictive disorders.

Authors:  Francesca Ducci; David Goldman
Journal:  Psychiatr Clin North Am       Date:  2012-06

Review 4.  Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome.

Authors:  Neal R Swerdlow
Journal:  Neurosci Biobehav Rev       Date:  2012-09-24       Impact factor: 8.989

5.  ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex.

Authors:  Katharina Domschke; Agnieszka Gajewska; Bernward Winter; Martin J Herrmann; Bodo Warrings; Andreas Mühlberger; Katherina Wosnitza; Evelyn Glotzbach; Annette Conzelmann; Andrea Dlugos; Manfred Fobker; Christian Jacob; Volker Arolt; Andreas Reif; Paul Pauli; Peter Zwanzger; Jürgen Deckert
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

6.  Catechol-O-methyltransferase genotype modulates opioid release in decision circuitry.

Authors:  Jennifer M Mitchell; James P O'Neil; William J Jagust; Howard L Fields
Journal:  Clin Transl Sci       Date:  2013-06-13       Impact factor: 4.689

7.  A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback.

Authors:  M R Lee; C L Gallen; T J Ross; P Kurup; B J Salmeron; C A Hodgkinson; D Goldman; E A Stein; M A Enoch
Journal:  Genes Brain Behav       Date:  2013-04-11       Impact factor: 3.449

Review 8.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study.

Authors:  Rebecca L Ashare; E Paul Wileyto; Kosha Ruparel; Patricia M Goelz; Ryan D Hopson; Jeffrey N Valdez; Ruben C Gur; James Loughead; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2013-09-14       Impact factor: 4.492

10.  Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers.

Authors:  Ayana A Gibbs; Carla E Bautista; Florence D Mowlem; Kris H Naudts; Dora T Duka
Journal:  J Psychiatry Neurosci       Date:  2014-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.